CRMTHIGH SIGNALREGULATORY10-K

CRMT filed a comprehensive restatement 10-K correcting material omissions in financial disclosures related to $436.1 million (28.9% of gross finance receivables) in systematic loan modifications for borrowers experiencing financial difficulty.

The company admitted to failing to provide required disclosures under ASC 310 for troubled debt restructurings affecting nearly 29% of their loan portfolio, indicating significant internal control weaknesses in financial reporting. This restatement raises serious questions about management's understanding of accounting requirements and the reliability of prior financial statements, particularly concerning given CRMT's role as a finance company where loan quality disclosures are fundamental to investor assessment.

Comparing 2025-08-08 vs 2024-07-15View on EDGAR →
FINANCIAL ANALYSIS

Despite the accounting irregularities, CRMT showed dramatic operational improvement with net income surging 305% to $51.3M and gross profit increasing 302% to $264.5M, though this was partially offset by a 57% increase in credit loss provisions to $257.1M. The company strengthened its balance sheet with stockholders' equity growing 21% to $569.4M and improved its cash position, while operating cash flow losses narrowed significantly from -$73.9M to -$48.8M. However, these strong financial results must be viewed cautiously given the material disclosure deficiencies that required comprehensive restatement.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+304.7%
$12.7M$51.3M

Net income grew 304.7% — bottom-line growth signals improving overall business health.

Gross Profit
P&L
+302.3%
$65.7M$264.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
+77.6%
$5.5M$9.8M

Cash position surged 77.6% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
+70.6%
$38.3M$65.3M

Interest expense surged 70.6% — significant debt increase or rising rates materially impacting earnings.

Provision for Credit Losses
P&L
+57.1%
$163.7M$257.1M

Credit loss provisions surged 57.1% — management flagging significant deterioration in loan quality ahead.

Capital Expenditure
Cash Flow
-36.7%
$6.1M$3.9M

Capex reduced 36.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+34%
-$73.9M-$48.8M

Operating cash flow surged 34% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+21%
$470.6M$569.4M

Equity base grew 21% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Share Buybacks
Cash Flow
+18.9%
$365K$434K

Share repurchases increased 18.9% — management returning capital, signals confidence in intrinsic value.

LANGUAGE CHANGES
NEW — 2025-08-08
PRIOR — 2024-07-15
ADDED
There were 8,277,627 shares of the registrant s common stock outstanding as of July 31, 2025.
( we or the Company ) is filing this comprehensive Annual Report on Form 10-K for the fiscal year ended April 30, 2025 (this Form 10-K ).
This comprehensive Form 10-K contains the restatement of the Company s Consolidated Financial Statements for the fiscal year ended April 30, 2024 and also includes restated disclosure information from each of the quarterly periods included in the Company s Quarterly Reports on Form 10-Q filed during the fiscal years ended April 30, 2025 and 2024.
These omitted disclosures relate to our systematic modification program affecting $436.1 million, or 28.9%, of the Company s gross finance receivables as of April 30, 2025.
As further described in Item 7, Management s Discussion and Analysis of Financial Condition and Results of Operations, included in Part II of this Form 10-K, in connection with the preparation of the Company s financial statements for the fiscal year ended April 30, 2025, the Company concluded that there were omissions in our prior period financial statements with respect to required disclosures under the Financial Accounting Standards Board s Accounting Standards Update ( ASU ) 2022-02, Financial Instruments Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures.
+7 more — sign up free →
REMOVED
There were 6,396,757 shares of the registrant s common stock outstanding as of July 11 , 2024 .
The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Over the last five fiscal years, the Company s annual provision for credit losses as a percentage of sales have ranged from a low of 19.31% in fiscal 2021 to 36.48% in fiscal 2024 (average of 26.36%).
During fiscal 2024, credit losses signaled a return to more normal pre-pandemic levels, but customers are still faced with continued inflationary pressure and increasing interest rates from federal monetary policy.
The percentage of credit loss as a percentage of sales was impacted by the lower sales revenue in fiscal 2024.
+7 more — sign up free →
MORE REGULATORY SIGNALS
BCHTHIGHBCHT has added extensive PFAS chemical definitions to their 10-K while removing ...
2026-03-31
OMERHIGHOMER achieved FDA approval for YARTEMLEA in December 2025, transforming from a c...
2026-03-31
UNCYHIGHThe FDA issued a Complete Response Letter (CRL) in June 2025 rejecting UNCY's dr...
2026-03-30
NVNOHIGHNVNO received a not-approvable letter from the FDA for its lead product VenoValv...
2026-03-26
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →